No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for ... facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology ... application of the technology, meaning that bone marrow stem cells are ...

But just because an ORF is translated into a protein doesn’t mean that the proteins are ... study their effects in cells: CRISPR–Cas9 gene editing. “Suddenly we could surgically take out ...

Casgevy is a one-time therapy that uses CRISPR/Cas9 gene-editing technology to modify ... be made available under a managed-access scheme, meaning further data will be collected as patients ...